-
Proceedings of the Royal Society of... Apr 1956
Topics: Humans; Pyoderma; Pyoderma Gangrenosum
PubMed: 13322930
DOI: No ID Found -
BMJ (Clinical Research Ed.) Oct 1991
Topics: Humans; Pyoderma; Scalp Dermatoses; Skin Ulcer
PubMed: 1933018
DOI: 10.1136/bmj.303.6807.925-a -
Actas Dermo-sifiliograficas Mar 2012Pyoderma gangrenosum is a condition that is included among the neutrophilic dermatoses. Given its low incidence, few studies have addressed its epidemiology or treatment. (Review)
Review
BACKGROUND
Pyoderma gangrenosum is a condition that is included among the neutrophilic dermatoses. Given its low incidence, few studies have addressed its epidemiology or treatment.
OBJECTIVE
To describe the epidemiological and clinical characteristics of patients with pyoderma gangrenosum along with our experience of treating the condition in a referral hospital in Malaga, Spain.
MATERIAL AND METHODS
A retrospective, observational study was undertaken in the Department of Dermatology at Hospital Clínico Universitario Virgen de la Victoria in Malaga, Spain between January 2000 and December 2009 and included all patients diagnosed with pyoderma gangrenosum.
RESULTS
The incidence of pyoderma gangrenosum in our reference population is 3.26 cases per million inhabitants per year. The most frequent concomitant systemic disease was ulcerative colitis (5 cases, 33%). In 4 patients with that disease, pyoderma gangrenosum appeared during a flare-up. In 80% of cases, patients were not referred to a dermatologist during the initial phase of pyoderma gangrenosum, and most referrals were from gastroenterology or general surgery (4 patients each, 52%).
CONCLUSIONS
Patients with pyoderma gangrenosum are often referred to dermatologists by other specialists after a varying period of time has elapsed without achieving an accurate diagnosis. In these patients, especially those between 20 and 40 years of age, it is essential to rule out concomitant disease. Adalimumab is a good treatment option for pyoderma gangrenosum.
Topics: Adult; Aged; Biopsy; Colitis, Ulcerative; Comorbidity; Delayed Diagnosis; Dermatology; Female; Gastroenterology; General Surgery; Hospitals, University; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Pyoderma Gangrenosum; Referral and Consultation; Retrospective Studies; Skin Ulcer; Spain
PubMed: 21782147
DOI: 10.1016/j.ad.2011.04.010 -
PloS One 2015We conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma. (Meta-Analysis)
Meta-Analysis Review
OBJECTIVE
We conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
METHODS
PubMed was systematically searched for impetigo or pyoderma studies published between January 1 1970 and September 30 2014. Two independent reviewers extracted data from each relevant article on the prevalence of impetigo.
FINDINGS
Sixty-six articles relating to 89 studies met our inclusion criteria. Based on population surveillance, 82 studies included data on 145,028 children assessed for pyoderma or impetigo. Median childhood prevalence was 12·3% (IQR 4·2-19·4%). Fifty-eight (65%) studies were from low or low-middle income countries, where median childhood prevalences were 8·4% (IQR 4·2-16·1%) and 14·5% (IQR 8·3-20·9%), respectively. However, the highest burden was seen in underprivileged children from marginalised communities of high-income countries; median prevalence 19·4%, (IQR 3·9-43·3%).
CONCLUSION
Based on data from studies published since 2000 from low and low-middle income countries, we estimate the global population of children suffering from impetigo at any one time to be in excess of 162 million, predominantly in tropical, resource-poor contexts. Impetigo is an under-recognised disease and in conjunction with scabies, comprises a major childhood dermatological condition with potential lifelong consequences if untreated.
Topics: Child; Child, Preschool; Humans; Impetigo; Prevalence; Pyoderma; Socioeconomic Factors
PubMed: 26317533
DOI: 10.1371/journal.pone.0136789 -
Internal Medicine (Tokyo, Japan) Feb 2023
Topics: Humans; Pyoderma Gangrenosum; Colitis, Ulcerative; Stomatitis; Gingivitis, Necrotizing Ulcerative; Colectomy
PubMed: 35871595
DOI: 10.2169/internalmedicine.9802-22 -
Journal of Ayub Medical College,... 2023The first description of Pyoderma gangrenosum (PG) was made about a century ago. It is difficult to understand the aetiology, pathophysiology, and therapy of PG. This... (Review)
Review
The first description of Pyoderma gangrenosum (PG) was made about a century ago. It is difficult to understand the aetiology, pathophysiology, and therapy of PG. This disease is believed to be caused by a systemic inflammatory response to neutrophil chemotaxis and faulty innate immune system control. Nearly fifty percent of the cases have underlying systemic symptoms. Significant improvements in PG management have been made over the years. The main goals of treatment are to reduce inflammation and speed up the healing of the PG wound. Even though the most recent medicines show promise, they are found on isolated case reports. The majority of patients are typically managed with topical treatment and local wound care, while resistant cases necessitate immunosuppressive medications. More progress can be made with improvements in technology in deciphering this complex disease and getting a greater understanding of the condition. The present standard therapies for refractory PG are not well supported by studies. In refractory PG, corticosteroids and cyclosporine have historically been administered. Tumour necrosis factor inhibitors are becoming a viable option; nonetheless, this requires careful research and upkeep. This review intended to describe the current trends in managing the PG. Several next-generation treatment options including the conventional therapies introduced to treat PG. We encompass the advantages and disadvantages of new treatments for PG.
Topics: Humans; Pyoderma Gangrenosum; Inflammation; Administration, Topical
PubMed: 38406909
DOI: 10.55519/JAMC-S4-12085 -
Advances in Wound Care Dec 2020Pyoderma gangrenosum (PG) is a rare neutrophilic ulcerative dermatosis that poses a high burden of morbidity due to underdiagnosis, resistance to therapy, and limited... (Review)
Review
Pyoderma gangrenosum (PG) is a rare neutrophilic ulcerative dermatosis that poses a high burden of morbidity due to underdiagnosis, resistance to therapy, and limited therapeutic options. Optimization of wound care strategies and multimodal anti-inflammatory approaches are necessary to mitigate multiple converging pathways of inflammation leading to delayed healing, which is further complicated by additional factors such as pathergy. PG treatment typically involves reducing inflammation, controlling pain, promoting wound healing, and treating the underlying etiology. Recent advances have been made with regard to targeted therapies for PG with topical, intralesional, and systemic medications. Wound management includes gentle cleansing without sharp debridement, limited topical antibacterial use, and maintenance of a moist environment to promote epithelial migration. Wound dressings and compression therapy, in particular, introduce a wide variety of therapeutic options. Dressings should aim to target the specific PG wound type, depending on the depth and exudative nature of the wound, as well as local secondary factors. Superficial wounds, eschar, exudative wounds, granulating wounds, and colonized wounds are managed with variable approaches to the same underlying principles of pathergy avoidance, moisture balance, and reduction of immunogenic inflammatory stimuli. The importance of compression therapy to decrease edema and overgranulation fits within this treatment paradigm. As each of these treatment modalities offers a complex mixture of advantages and limitations, development of a systematic treatment algorithm in the future can help direct a more tailored path toward wound healing.
Topics: Administration, Topical; Anti-Inflammatory Agents; Compression Bandages; Critical Care; Debridement; Humans; Pyoderma Gangrenosum; Wound Healing
PubMed: 32320358
DOI: 10.1089/wound.2020.1168 -
BMJ Case Reports Aug 2022The a priori risk of infection is high when a patient presents with an ulcerative skin condition and elevated inflammatory parameters. If the ulceration is progressive...
The a priori risk of infection is high when a patient presents with an ulcerative skin condition and elevated inflammatory parameters. If the ulceration is progressive despite adequate antibiotic therapy and tissue cultures are negative, pyoderma gangrenosum should be considered as the diagnosis. This rare infection mimicking skin condition can develop and worsen due to surgery. In this paper, we report two cases that illustrate the importance of making this clinical diagnosis in a timely manner in order to avoid unnecessary surgical interventions and worsening of the clinical picture.
Topics: Humans; Pyoderma Gangrenosum; Skin; Skin Ulcer; Anti-Bacterial Agents
PubMed: 37198754
DOI: 10.1136/bcr-2021-247770 -
Wounds : a Compendium of Clinical... Jun 2019Pyoderma gangrenosum (PG) is a rare, ulcerative inflammatory skin disease that most commonly occurs in patients with inflammatory bowel disease, rheumatologic diseases,... (Review)
Review
Pyoderma gangrenosum (PG) is a rare, ulcerative inflammatory skin disease that most commonly occurs in patients with inflammatory bowel disease, rheumatologic diseases, or hematologic diseases. Successful treatment of PG often requires immunosuppression and appropriate wound care. Systemic corticosteroids and cyclosporine are the first-line treatments for PG. However, chronic use of these systemic agents places patients at risk for developing significant side effects, including hyperglycemia, osteoporosis, hypertension, and weight gain. Furthermore, when treating small or superficial PG ulcers, the use of local agents as monotherapies or adjuvant treatments can be ideal to control inflammation and promote healing without placing the patient at risk for many severe side effects that can be seen with long-term use of systemic agents. This literature review assesses all available local therapies in order to summarize the use and reported efficaciousness of the broad range of local treatments available for PG.
Topics: Administration, Topical; Female; Humans; Immunosuppressive Agents; Injections, Intralesional; Male; Prognosis; Pyoderma Gangrenosum; Risk Assessment; Severity of Illness Index; Treatment Outcome
PubMed: 31215868
DOI: No ID Found -
Polskie Archiwum Medycyny Wewnetrznej Sep 2016
Topics: Adenine; Cyclosporine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prednisone; Pyoderma Gangrenosum; Pyrazoles; Pyrimidines
PubMed: 27698335
DOI: 10.20452/pamw.3578